J Korean Med Sci.  1987 Sep;2(3):157-165. 10.3346/jkms.1987.2.3.157.

A clinical study of topical mucopolysaccharides and polydeoxyribonucleoprotein (Foltene) therapy in alopecia

• Lee KS
• Myung KB
• Kook HI

• KMID: 1421262
• DOI: http://doi.org/10.3346/jkms.1987.2.3.157

Abstract

We performed clinical trials to evaluate the therapeutic effects of Foltene in patients of the several types of hair fallings. Thirty patients with male pattern baldness, alopecia areata and seborrheic alopecia were included in this study. Foltene was applied every other day for 40 days, and followed by maintenance therapy of twice application a week. The duration of whole therapy was 6 months. We conclude that Foltene is an effective and agent for male pattern baldness, alopecia areata and seborrheic alopecia from the following results. Ten patients with male pattern baldness was treated with Foltene for 6 months. Foltene had therapeutic effects of 50% in hair regrowth, 70% in decreased hair falls, 30% in decreased dandruff, 50% in decreased seborrhea. Thirteen patients with alopecia areata was treated with Foltene for 6 months. Foltene had therapeutic effects of 61.6% in hair regrowth, 53.9% in decreased in hair falls, 53.9% in decreased dandruff, 77.0% in decreased seborrhea. Seven patients with seborrheic alopecia was treatment with Foltene for 6 months. Foltene had therapeutic effects of 85.8% in hair regrowth, 57.2% in decreased hair falls, 42.9% in decreased dandruff, 85.8% in decreased seborrhea. The degree of therapeutic success was related to the duration of therapy. The side effects were as followed: itching sensation developed in 2 patients (6.7%); tingling sensation in 3 patients (10.0%); burning sensation in 1 patient (3.3%); erythema in 3 patients (10.0%).

Keyword

Mucopolysaccharides and Polydeoxyribonucleoprotein; Alopecia

MeSH Terms

Administration, Topical
Adolescent
Adult
Alopecia/*drug therapy/genetics
Child
Child, Preschool
Deoxyribonucleoproteins/*therapeutic use
Female
Glycosaminoglycans/adverse effects/*therapeutic use
Humans
Male
Deoxyribonucleoproteins
Glycosaminoglycans